Related Experiment Video
Updated: Mar 25, 2026
09:07
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
621
Exploring Cyclo (-Gly-Pro) for inflammation modulation in atopic dermatitis: a study on streptococcal postbiotics
Haeun Lee1, Yunseok Oh2, Tae-Won Seo3
1R&I Center, COSMAX BTI, Inno-Valley E, 255, Pangyo-ro, Bundang-gu, Seongnam-si, 13486, Republic of Korea.
Genes & Genomics
|March 24, 2026
Summary
Researchers identified Cyclo (-Gly-Pro), a postbiotic compound from skin bacteria, as a potential treatment for atopic dermatitis (AD). Further research is needed to explore its therapeutic role in managing this chronic skin condition.
Area of Science:
- Microbiology
- Dermatology
- Biochemistry
Background:
- Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting quality of life.
- AD pathogenesis involves genetic, environmental, and immune factors, with skin barrier defects and Staphylococcus aureus colonization being key.
- Postbiotics, derived from probiotics, offer potential therapeutic avenues for AD.
Purpose of the Study:
- To investigate a postbiotic solution from human skin Streptococcus isolates.
- To identify a core bioactive compound and its therapeutic potential in atopic dermatitis.
Main Methods:
- Quantification of Cyclo (-Gly-Pro) using GC-MS and GC-FID.
- Assessment of the compound's impact on inflammatory biomarkers in an AD-like keratinocyte model.
- Analysis of skin microbiome changes in AD patients post-treatment via 16S V3-V4 amplicon sequencing.
Main Results:
- Cyclo (-Gly-Pro) was consistently found in all tested Streptococcus strains.
- Compound production was inversely related to incubation temperature, optimal at 25°C.
- Optimized production and synergistic effects may enhance therapeutic efficacy.
Conclusions:
- Findings support further in vivo research for Cyclo (-Gly-Pro) in AD.
- Elucidating mechanisms can validate its role in novel dermatological therapies.
- This postbiotic compound shows promise for future AD treatment strategies.
Related Concept Videos
01:28Inflammatory Response
18.4K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
18.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
614
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
614
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
728
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
728
01:29Inflammatory Bowel Disease IV: Pharmacological Management
917
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
917
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K